Biotech News
Related news
ERASErasca2026-11-20 12:00 EST
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
ERASErasca2026-11-17 23:40 EST
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
FATEFate Therapeutics2026-11-10 12:00 EST
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
GERNGeron2026-11-04 14:00 EST
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
IDYAIDEAYA Biosciences2026-10-19 10:00 EST
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
GSKGSK plc2026-10-16 13:49 EST
GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026
CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-11-20 12:00 EST
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
ERASErasca2026-11-17 23:40 EST
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
ERASErasca2026-11-16 13:01 EST
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
ERASErasca2026-11-12 21:01 EST
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERASErasca2026-11-04 13:30 EST
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Stock data
- Close
- 14.22 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
